American Healthcare REIT price target raised to $32 from $30 at Truist

Truist raised the firm’s price target on American Healthcare REIT (AHR) to $32 from $30 and keeps a Buy rating on the shares. The firm lowered its 2025 and 2026 estimates, mostly due to the recent property dispositions and equity offering. Lower financial leverage and an improved cost of capital could help fuel stronger external growth, and the firm raised its same-store net operating income growth projection following better recent same-store results and 2025 guidance than previously modeled, the analyst tells investors in a research note. The company has among the strongest balance sheets and highest earnings growth profiles in Truist’s coverage universe, the firm adds.